Cracking the ERG code in prostate cancer
Parabilis has achieved the first pharmacological proof-of-concept for degrading the long-considered ‘undruggable’ transcription factor ERG in prostate cancer. DDW’s Megan Thomas speaks with Dr Jonathan Hurov, Executive Vice President, Discovery Biology at Parabilis Medicines, about the milestone.
MT: ERG has been considered ‘undruggable’ for decades. Why is this?
JH: ERG has been a long-recognised high-value target in prostate cancer, where ERG fusions have been implicated in 40-50% of all cases. ERG has been undruggable (until now) by conventional approaches because it lacks small molecule binding pockets.
MT: How does your novel approach for degrading ERG differ from what has failed in the past?
JH: The key to our progress on this programme is our ability to discover high affinity Helicon peptide binders of ERG as starting points for drug discovery. In addition, unlike small molecules, Helicons have multiple well-tolerated points of E-3 ligand attachment, increasing the likelihood of ternary complex formation and successful target degradation.
Potent and specific degradation of ERG has been achieved with Helicon peptide degraders both in vitro and in vivo, leading to substantial tumour growth inhibition in multiple mouse models of prostate cancer. The data represents the first pharmacological proof-of-concept for ERG dependency in preclinical models of ERG-fusion positive prostate cancer.
MT: What specific challenges did you face in targeting ERG and how did you overcome these?
JH: There are several features of this programme that make it challenging. First, as already noted, our Helicon platform was key to enabling identification of ERG binding hits of interest on the road to a drug. The platform has been developed over multiple years to enable target binding site predictions, hit ID using both phage display screening and computational drug discovery, and lead optimisation to IND, all supported by proprietary data and AI modelling that is bespoke for Helicon peptides.
Second, ERG is part of a larger family of transcription factors called the ETS family of transcription factors. This leads to requiring both an understanding of the requirement for selectivity of our drug for ERG (versus other family members), and the ability to make a drug that achieves that desired selectivity.
Finally, the biology of ERG is not as well understood as some other prevalent oncogenes (like b-catenin and KRAS), so we have been spending some time elucidating this biology with our Helicons as the programme has progressed.
MT: Your AACR presentation showed >90% ERG degradation in vivo. How do you interpret the relationship between ERG knockdown and observed tumour growth inhibition in your preclinical models?
JH: In mice implanted with prostate cancer cell-derived xenograft (CDX) tumours, administration of the ERG degrader produced >90% tumour ERG degradation through seven days post dose. This corresponded to suppression of ERG’s downstream effects on target genes like ARHGBID and to strong efficacious responses. We are still building our understanding of the PD/efficacy relationship across multiple different models.
In both patient-and cell-line derived xenograft (PDX and CDX) models of TPM2SS2-ERG fusion prostate cancer, Parabilis’s ERG degrader significantly inhibited tumour growth.
One of the key downstream effectors of ERG degraders in tumour growth inhibition is likely Myc, which is downregulated in tumours with ERG inhibition.
MT: Can you elaborate on any other data you presented at AACR and what this means for the future of both the company as well as for protein degradation?
JH: The data we shared for our ERG degrader programme is exciting for the company and the prostate cancer field because we should finally be able to assess the role of this oncogene in patients. From a company perspective, this programme also represents a compelling second proof of concept (after FOG-001, our b-catenin inhibitor) for the platform and illustrates our ability to reproducibly drug high value targets.
These are also our first proof of concept data for our novel approach to degradation using Helicons as bifunctional degraders.
MT: Beyond ERG, are there other transcription factors or ‘undruggable’ proteins on your radar to which this approach could be applied?
JH: Parabilis’s prostate cancer franchise also includes a selective degrader of active androgen receptor (ARON), which binds at a site unique from approved drugs, and which will circumvent known resistance mechanisms that arise in response to current AR antagonist therapies.
MT: What are the key milestones you expect to reach over the next year? How about the next five years?
The company anticipates entering IND-enabling toxicology studies in 2025 for the ERG degrader programme. We will continue to build our pipeline with impactful medicines and strengthen our platform capabilities as we move through the upcoming five years.
Biography
Dr Jonathan Hurov is Executive Vice President, Discovery Biology at Parabilis Medicines (formerly FogPharma), a clinical-stage biopharmaceutical company advancing a new category of ultra-tunable peptide therapeutics. Hurov’s expertise in oncology drug discovery and platform biology informs his leadership of Parabilis’s discovery biology, proteomics and biochemistry teams.
